Literature DB >> 18841094

Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells?

Etienne Puymirat1, Raghed Geha, André Tomescot, Valérie Bellamy, Jérôme Larghero, Ludovic Trinquart, Patrick Bruneval, Michel Desnos, Albert Hagège, Michel Pucéat, Philippe Menasché.   

Abstract

Mesenchymal stem cells (MSCs) are reported to be immune privileged. We assessed whether their transplantation (Tx) could create a suppressive microenvironment mitigating rejection of coinjected human embryonic stem cells (hESCs). Three weeks after ligation-induced myocardial infarction, 40 immunocompetent rats received 150 microl of cardiac-specified hESCs (5 x 10(6)), MSCs (5 x 10(6)), hESC + MSC (5 x 10(6) for each), or control medium. Two months after Tx, left ventricle (LV) function was assessed by echocardiography, and hearts were processed for the detection of human cells by immunostaining and quantitative RT-PCR, patterns of rejection, fibrosis, and angiogenesis. Two months after Tx, LV ejection fraction (LVEF) was significantly higher in the ESC and ESC + MSC groups compared with controls. There were few engrafted cells, which expressed markers of endothelial, smooth muscle, and ventricular cardiac cells, particularly in the MSC group. Hearts of all groups demonstrated a similar infiltration by CD4(+) and CD3(+) cells but MSC-Tx resulted in a greater infiltration of FoxP3 compared with the control and ESC-alone groups. No teratoma was observed. Thus, cotransplantation of ESCs and MSCs provided better functional preservation compared with single-cell treatment alone. However, there was only modest evidence for an immunosuppressive effect of coinjected MSCs and their beneficial effects seemed rather mediated by trophic effects on the host tissue.

Entities:  

Mesh:

Year:  2008        PMID: 18841094      PMCID: PMC2834983          DOI: 10.1038/mt.2008.208

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  42 in total

Review 1.  Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy.

Authors:  Jeffrey M Zimmet; Joshua M Hare
Journal:  Basic Res Cardiol       Date:  2005-11       Impact factor: 17.165

Review 2.  Mesenchymal stem cells: a new strategy for immunosuppression?

Authors:  Antonio Uccelli; Vito Pistoia; Lorenzo Moretta
Journal:  Trends Immunol       Date:  2007-04-02       Impact factor: 16.687

3.  Stem cell differentiation requires a paracrine pathway in the heart.

Authors:  Atta Behfar; Leonid V Zingman; Denice M Hodgson; Jean-Michel Rauzier; Garvan C Kane; Andre Terzic; Michel Pucéat
Journal:  FASEB J       Date:  2002-10       Impact factor: 5.191

4.  Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

Authors:  Alma J Nauta; Geert Westerhuis; Alwine B Kruisselbrink; Ellie G A Lurvink; Roel Willemze; Willem E Fibbe
Journal:  Blood       Date:  2006-05-11       Impact factor: 22.113

5.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

6.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.

Authors:  B Arnulf; S Lecourt; J Soulier; B Ternaux; M-Noelle Lacassagne; A Crinquette; J Dessoly; A-K Sciaini; M Benbunan; C Chomienne; J-P Fermand; J-P Marolleau; J Larghero
Journal:  Leukemia       Date:  2006-11-09       Impact factor: 11.528

7.  Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells.

Authors:  Micha Drukker; Helena Katchman; Gil Katz; Smadar Even-Tov Friedman; Elias Shezen; Eran Hornstein; Ofer Mandelboim; Yair Reisner; Nissim Benvenisty
Journal:  Stem Cells       Date:  2005-08-18       Impact factor: 6.277

8.  Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation.

Authors:  Kirsten A Keyser; Karen E Beagles; Hans-Peter Kiem
Journal:  Cell Transplant       Date:  2007       Impact factor: 4.064

9.  Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats.

Authors:  André Tomescot; Julia Leschik; Valérie Bellamy; Gilbert Dubois; Emmanuel Messas; Patrick Bruneval; Michel Desnos; Albert A Hagège; Michal Amit; Joseph Itskovitz; Philippe Menasché; Michel Pucéat
Journal:  Stem Cells       Date:  2007-05-31       Impact factor: 6.277

10.  The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells.

Authors:  Hua Liu; David Michael Kemeny; Boon Chin Heng; Hong Wei Ouyang; Alirio J Melendez; Tong Cao
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

View more
  8 in total

Review 1.  Embryonic stem cells for severe heart failure: why and how?

Authors:  Philippe Menasché
Journal:  J Cardiovasc Transl Res       Date:  2012-03-13       Impact factor: 4.132

2.  Use of Encapsulated Stem Cells to Overcome the Bottleneck of Cell Availability for Cell Therapy Approaches.

Authors:  D Freimark; P Pino-Grace; S Pohl; C Weber; C Wallrapp; P Geigle; R Pörtner; P Czermak
Journal:  Transfus Med Hemother       Date:  2010-03-08       Impact factor: 3.747

Review 3.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

4.  Co-transplantation of syngeneic mesenchymal stem cells improves survival of allogeneic glial-restricted precursors in mouse brain.

Authors:  Amit K Srivastava; Camille A Bulte; Irina Shats; Piotr Walczak; Jeff W M Bulte
Journal:  Exp Neurol       Date:  2015-10-26       Impact factor: 5.330

Review 5.  Stem cell therapy for chronic myocardial infarction.

Authors:  Manuel Mazo; Beatriz Pelacho; Felipe Prósper
Journal:  J Cardiovasc Transl Res       Date:  2010-01-21       Impact factor: 4.132

6.  Cardiac Cell Therapy 3.0: The Beginning of the End or the End of the Beginning?

Authors:  Konstantinos E Hatzistergos; Anastasia Vedenko
Journal:  Circ Res       Date:  2017-07-07       Impact factor: 17.367

Review 7.  Stem Cells and Progenitor Cells for Tissue-Engineered Solutions to Congenital Heart Defects.

Authors:  Yang Gao; Jeffrey G Jacot
Journal:  Biomark Insights       Date:  2015-08-26

Review 8.  Next generation of heart regenerative therapies: progress and promise of cardiac tissue engineering.

Authors:  Miguel F Tenreiro; Ana F Louro; Paula M Alves; Margarida Serra
Journal:  NPJ Regen Med       Date:  2021-06-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.